中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 8
Aug.  2012
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2012  >  28(8): 628-632

Recent treatment advances for hepatitis C virus-related mixed cryoglobulinemia

Research funding:

 

  • Published Date: 2012-08-20
    Abstract
  • Mixed cryoglobulinemia is a chronic immune complex-mediated disease that is closely associated with hepatitis C virus (HCV) infection.The vasculitis effect of this disease, involving small or middle-sized arteries and veins, manifests upon sedimentation of complexes of antigen, cryoglobulin, and complement in the vessel walls.The main clinical symptoms of mixed cryoglobulin vasculitis include a triad of palpable purpura, arthralgias and weakness.Other pathological signs include glomerulonephritis, peripheral neuropathy, skin ulcers, and widespread vasculitis.Heterogeneous presentation complicates treatment strategies, especially for patients with underlying HCV infection.The current treatment strategies for HCV-related mixed cryoglobulinemia are discussed in this review, including anti-HCV therapies, inhibition of B cell clonal proliferation, and inhibition of cryoglobulin production.In addition, the palliative treatments used to improve the related symptoms and signs are touched upon.While many treatment options exist, the most appropriate treatment strategy must be selected on an individual patient basis by analysis of disease activity and severity of organ damage.

     

    • FullText(HTML)
    • References(45)
  • [1] Jacobson IM, Cacoub P, Dal Maso L, et al. Manifestations of chronic hepatitis C virus infection beyond the liver[J]. Clin Gastroenterol Hepatol, 2010, 8 (12) : 1017-1029.
    [2]Ramos-Casals M, Stone JH, Cid MC, et al.The cryoglobu-linaemias[J].Lancet, 2012, 379 (9813) :348-360.
    [3]St Clair EW.Hepatitis C virus-related cryoglobulinemic vas-culitis:emerging trends intherapy[J].Arthritis Rheum, 2012, 64 (3) :604-608.
    [4]Nicolau A, T n sescu R, B l nescu E, et al.Hepatitis C vi-rus-mixed cryoglobulinemia-lymphoma relationship[J].Rom J Intern Med, 2011, 49 (1) :3-10.
    [5]Disdier P, Harle JR, Weiller PJ.Cryoglobulinemia and hepa-titis C virus infection[J].Lancet, 1991, 338 (8775) :1151-1152.
    [6] Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia[J]. N Engl J Med, 1992, 327 (21) : 1490-1495.
    [7]Misiani R, Bellavita P, Fenili D, et al.Hepatitis C virus infec-tion in patients with essential mixed cryoglobulinemia[J].Ann Intern Med, 1992, 117 (7) :573-577.
    [8]Gorevic PD, Frangione B.Mixed cryoglobulinemia crossreac-tive idiotypes:Implications for the relationship of MC to rheu-matic and lymphoproliferative diseases[J].Semin Hematol, 1991, 28 (2) :79-94.
    [9]Padmanabhan P, Dixit NM.Mathematical model of viral ki-netics in vitro estimates the number of E2-CD81 complexesnecessary for hepatitis C virus entry[J].PLoS Comput Biol, 2011, 7 (12) :e1002307.
    [10]Monti G, Pioltelli P, Saccardo F, et al.Incidence and charac-teristics of non-Hodgkin lymphomas in a multicenter casefile of patients with hepatitis C virus-related symptomaticmixed cryoglobulinemias[J].Arch Intern Med, 2005, 165 (1) :101-105.
    [11]Kayali Z, Buckwold VE, Zimmerman B, et al.Hepatitis C, cryoglobulinemia, and cirrhosis:a meta-analysis[J].Hep-atology, 2002, 36 (4) :978-985.
    [12] Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review[J]. Metab Brain Dis, 2004, 19 (3-4) : 357-381.
    [13] Iannuzzella F, Vaglio A, Garini G. Management of hepatitis C virus-related mixed cryoglobulinemia [J]. Am J Med, 2010, 123 (5) : 400-408.
    [14]Ferri C, Sebastiani M, Giuggioli D, et al.Mixed cryoglobu-linemia:demographic, clinical, and serologic features andsurvival in 231 patients[J].Semin Arthritis Rheum, 2004, 33 (6) :355-374.
    [15]Groves C, Devereux C, McMillan C.A case of cutaneous vas-culitis with underlying hepatitis C and cryoglobulinaemia[J].Ul-ster Med J, 2008, 77 (1) :51-53.
    [16]Lo KY, Chen CY, Lee CS.Hepatitis C virus-associated typeII mixed cryoglobulinemia vasculitis complicated with mem-branous proliferative glomerulonephritis[J].Ren Fail, 2009, 31 (2) :149-152.
    [17]Morales JM, Kamar N, Rostaing L.Hepatitis C and renal dis-ease:epidemiology, diagnosis, pathogenesis and therapy[J].Contrib Nephrol, 2012, 176:10-23.
    [18]Zaltron S, Puoti M, Liberini P, et al.High prevalence of pe-ripheral neuropathy in hepatitis C virus infected patients withsymptomatic and asymptomatic cryoglobulinemia[J].Ital JGastroent erol Hepatol, 1998, 30 (4) :391-395.
    [19]Boukhris S, Magy L, Senga-mokono U, et al.Polyneurop-athy with demyelinating features in mixed cryoglobulinemiawith hepatitis C virus infection[J].Eur J Neurol, 2006, 13 (9) :937-941.
    [20]Alpa M, Ferrero B, Cavallo R, et al.Anti-neuronal antibod-ies in patients with HCV-related mixed cryoglobulinemia[J].Autoimmun Rev, 2008, 8 (1) :56-58.
    [21]Lee YH, Ji JD, Yeon JE, et al.Cryoglobulinemia and rheu-matic manifestations in patients with hepatitis C virus infec-tion[J].Ann Rheum Dis, 1998, 57 (12) :728-731.
    [22]Sene D, Ghillani-Dalbin P, Limal N, et al.Anti-cyclic cit-rullinated peptide antibodies in hepatitis C virus associatedrheumatological manifestations and Sj gren’s syndrome[J].Ann Rheum Dis, 2006, 65 (3) :394-397.
    [23]Gisbert JP, Garcia-Buey L, Pajares JM, et al.Prevalence ofhepatitis C virus infection in B-cell non-Hodgkin’s lympho-ma:systematic review and meta-analysis[J].Gastroenter-ology, 2003, 125 (6) :1723-1732.
    [24] Wang CC, Kao JH. Hepatitis C virus infection, lipids, and coronary heart disease: a Pandora's box[J]. Hepatology, 2010, 51 (1) : 343-344.
    [25] Aliannejad R, Ghanei M. Hepatitis C and pulmonary fibrosis: Hepatitis C and pulmonary fibrosis [J]. Hepat Mon, 2011, 11 (2) : 71-73.
    [26] Kallemuchikkal U, Gorevic PD. Evaluation of cryoglobulins[J]. Arch Pathol Lab Med, 1999, 123 (2) : 119-125.
    [27] NIH Consensus Statement on Management of Hepatitis C: 2002[J]. NIH Consens State Sci Statements, 2002, 19 (3) : 1-46.
    [28]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon al-fa-2a plus ribavirin for chronic C virus infection[J].N EnglJ Med, 2002, 347 (13) :975-982.
    [29]Campise M, Tarantino A.Glomerulonephritis in mixed cryo-globulinemia:what treatment?[J].Nephrol Dial Transplant, 1999, 14 (2) :281-283.
    [30]Pietrogrande M, De Vita S, Zignego AL, et al.Recommen-dations for the management of mixed cryoglobulinemia syn-drome in hepatitis C virus-infected patients[J].AutoimmunRev, 2011, 10 (8) :444-454.
    [31] Won D, Park CJ, Chang JW. Cryoglobulinemic vasculitis and monoclonal gammopathy in end-stage renal disease[J]. Korean J Hematol, 2011, 46 (4) : 215.
    [32]Koukoulaki M, Jayne DR.Mycophenolate mofetil in anti-neu-trophil cytoplasm antobodies-associated systemic vasculitis[J].Nephron Clin Pract, 2006, 102 (3-4) :c100-107.
    [33] Ramos-Casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection [J]. Lupus, 2005, 14 (Suppl 1) : s64-s72.
    [34] Laurino S, Borrelli S, Catapano F, et al. Treatment of HCV-associated cryoglobulinemic glomerulonephritis[J]. G Ital Nefrol, 2009 , 26 (3) : 318-327.
    [35] Pons-Estel GJ, Salerni GE, Serrano RM, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature[J]. Autoimmun Rev, 2011, 10 (11) : 679-684.
    [36]Ramunni A, Lauletta G, Brescia P, et al.Double-filtrationplasmapheresis in the treatment of leg ulcers in cryoglobu-linemia[J].J Clin Apher, 2008, 23 (3) :118-122.
    [37]Ferri C, Cacoub P, Mazzaro C, et al.Treatment with ritux-imab in patients with mixed cryoglobulinemia syndrome:re-sults of multicenter cohort study and review of the literature[J].Autoimmun Rev, 2011, 11 (1) :48-55.
    [38]Dammacco F, Tucci FA, Lauletta G, et al.Pegylated inter-feron-alpha, ribavirin, and rituximab combined therapy ofhepatitis Cvirus-related mixed cryoglobulinemia:a long-term study[J].Blood, 2010, 116 (3) :343-353.
    [39]Booth A, Harper L, Hammad T, et al.Prospective study ofTNFalpha blockade with infliximab in anti-neutrophil cyto-plasmic antibody-associated systemic vasculitis[J].J AmSoc Nephrol, 2004, 15 (3) :717-721.
    [40]Galeazzi M, Bellisai F, Giannitti C, et al.Safety of cyclospor-in A in HCV-infected patients experience with cyclosporin Ain patients affected by disorders and concomitant HCV infec-tion[J].Ann N Y Acad Sci, 2007, 1110:544-549.
    [41]Attal N, Cruccu G, Baron R, et al.EFNS guidlines on phar-macological treatment of neuropathic pain:2010 Revision[J].Eur J Neurol, 2010, 17 (9) :1113-1123.
    [42]Lo Gullo R, De Filippis L, Caliari A, et al.Successful treat-ment of necrotizing vasculitic lesions after infusion of iloprostin a patient with cryoglobulinemia and chronic HCV infection[J].Clin Exp Rheumatol, 2005, 23 (6) :912-913.
    [43]Monti G, Saccardo F, Rinaldi G, et al.Colchicine in the treat-ment of mixed cryoglobulinemia[J].Clin Exp Rheumatol, 1995, 13 (Suppl 13) :s197-s199.
    [44]Bruchfeld A, Lindahl K, Stahle L, et al.Interferon and ribavi-rin treatment in patients with hepatitis C-associated renaldisease and renal insufficiency[J].Nephrol Dial Transplant, 2003, 18 (8) :1573-1580.
    [45]Saadoun D, Resche Rigon M, Sene D, et al.Rituximab plusPeg-interferon-alpha/ribavirin compared with Peg-inter-feron-alpha/ribavirin in hepatitis C-related mixed cryoglob-ulinemia[J].Blood, 2010, 116 (3) :326-334.
    • Relative Articles

  • Relative Articles

    [1]Yuanqian MIN, Shan LI, Xianghua LIU, Yi YANG, Ningning LI, Baoping LU. Research advances in the cascade interaction between reactive oxygen species/reactive nitrogen species and the NF-κB signaling pathway in liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(6): 1454-1460. doi: 10.3969/j.issn.1001-5256.2023.06.031
    [2]Cheng MA, Hui YANG. Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease[J]. Journal of Clinical Hepatology, 2023, 39(7): 1708-1713. doi: 10.3969/j.issn.1001-5256.2023.07.028
    [3]Linzhang ZHANG, Dingqi ZHANG, Ying XU, Hailin YANG, Shenglan QI, Congcong ZHANG, Jiamei CHEN, Ping LIU, Wei LIU. Cultured mycelia of Cordyceps sinensis exerts a protective effect on a mouse model of liver fibrosis by inhibiting the Toll-like receptor 4/nuclear transcription factor-κB signaling pathway and angiopoietin-like protein 4[J]. Journal of Clinical Hepatology, 2022, 38(7): 1540-1547. doi: 10.3969/j.issn.1001-5256.2022.07.016
    [4]Gege TIAN, Enrui XIA, Suyan ZHANG, Shunzhen ZHAGN, Furong XU. Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway[J]. Journal of Clinical Hepatology, 2021, 37(12): 2957-2962. doi: 10.3969/j.issn.1001-5256.2021.12.047
    [5]Zheng Yang, Wang JiaRu, Liu LuLu, Wang JiaHui, Zhao TieJian. Molecular mechanism of the anti-liver fibrosis effect of curcumol: An analysis based on the TLR4/NF-κB signaling pathway[J]. Journal of Clinical Hepatology, 2020, 36(7): 1508-1513. doi: 10.3969/j.issn.1001-5256.2020.07.013
    [6]Huang Jin, Zhang MeiQuan, He DaoXing. Expression of nuclear factor-kappa B and inducible nitric oxide synthase in peripheral blood mononucleated cells and immune status in patients with different stages of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(3): 536-540. doi: 10.3969/j.issn.1001-5256.2020.03.013
    [7]Yang DaYin, Du YiChao, Tan Peng, Chen Hao, Qian BaoLin, Wang AnKang, Huang ShiYao, Fu WenGuang, Xia XianMing. Effect of Hic-5 gene knockout on NF-κB/p65 expression and CCl4-induced liver fibrosis degree in mice[J]. Journal of Clinical Hepatology, 2019, 35(11): 2483-2488. doi: 10.3969/j.issn.1001-5256.2019.11.019
    [8]Sun TingTing, Li JingTao, Wei HaiLiang, Yan ShuGuang, Li Qian, Guo YingJun, Chang ZhanJie. Research advances in the role of the TNF-α/NF-κB signaling pathway in the regulation of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(9): 2095-2098. doi: 10.3969/j.issn.1001-5256.2019.09.047
    [9]Li ShuZhi, Liu TieJun. Effect of Duxiao Ganqing Pill on liver inflammation in rats with cirrhotic endotoxemia: An analysis based on the TLR4/MyD88/NF-κB signaling pathway[J]. Journal of Clinical Hepatology, 2019, 35(9): 1958-1964. doi: 10.3969/j.issn.1001-5256.2019.09.015
    [10]Zhu Hui, Ping Jian, Xu LieMing. Role of the nuclear factor-kappa B signaling pathway on the progress of hepatic fibrosis and the anti-fibrotic mechanism of traditional Chinese medicine[J]. Journal of Clinical Hepatology, 2018, 34(4): 858-861. doi: 10.3969/j.issn.1001-5256.2018.04.035
    [11]Ding Qian, Li Zhen, Liu Bin, Ling LiPing, Zhang ChunQing. Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action[J]. Journal of Clinical Hepatology, 2017, 33(3): 485-491. doi: 10.3969/j.issn.1001-5256.2017.03.018
    [12]Jiao ShuHua, Liu PengLiang, Wen YanHui. Combined determination of serum C-reactive protein,lipase,interleukin-1β,and intercellular adhesion molecule1 in early identification of severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(1): 131-134. doi: 10.3969/j.issn.1001-5256.2016.01.025
    [13]Wang Yan, Cui LiJian, Xiao HongLi, Wang GuoXing, Yin ChengHong. Effect of angiotensin 1-7 on the TLR4/NF-κB pathway in cerulein-induced pancreatic acinar cells[J]. Journal of Clinical Hepatology, 2016, 32(11): 2146-2150. doi: 10.3969/j.issn.1001-5256.2016.11.029
    [14]Ye Qing, Han Tao, Li Ning. Clinical value of serum soluble intercellular adhesion molecule-1 in patients with primary biliary cirrhosis and autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(5): 417-420. doi: 10.3969/j.issn.1001-5256.2014.05.008
    [15]Fan XiaoBin, Li WenXing, Chen BingHe, Xiong ZeYi, Duan JiMing. Effects of Forsythia suspensa on expression of NF-κB and Foxp3 during liver injury in rats with severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2013, 29(7): 503-507. doi: 1001-5256 (2013) 07-0503-05
    [16]Lu XiaoJu, Chen YongPing, Yang Tao, Shen ChunYan. Effect of baicalin of the expression of NF-κB in acute liver failure in rats[J]. Journal of Clinical Hepatology, 2011, 27(10): 1087-1092.
    [17]Li YaPing, Dang ShuangSuo, Zhai Song, Jia XiaoLi, Wang Yuan, Wang XiuFang, Wang WenJun, Li Mei. Immunohistochemical expression of NF-κB, α-SMA and TGFβ1 in experimental hepatic injury rats[J]. Journal of Clinical Hepatology, 2011, 27(11): 1207-1210.
    [18]Cheng LiangBin, Cheng Ming, Liu Yan. The effect of Kangxian ruangan granule on the expression of nuclear factor-κB gene in fibrotic rat liver[J]. Journal of Clinical Hepatology, 2010, 26(4): 410-412.
    [19]Hu TaiHong, Jiang XiangHu, Jiang YueMing, Zhou Min, Xu Min, Zhu Rui, Yang Ling. Expression of NF-κB and ERK-1mRNA in rat with liver fibrosis[J]. Journal of Clinical Hepatology, 2009, 25(1): 23-25.
    [20]Wu YanYan, Tong QiaoXia, He YongWen. Study on the effect of chondroitin sulfate on fibrotic liver induced by alcohol in rats[J]. Journal of Clinical Hepatology, 2007, 23(3): 188-190.
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-042024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-030510152025
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.0 %FULLTEXT: 2.0 %META: 95.7 %META: 95.7 %PDF: 2.3 %PDF: 2.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.3 %其他: 4.3 %其他: 1.0 %其他: 1.0 %上海: 2.0 %上海: 2.0 %丽水: 0.7 %丽水: 0.7 %北京: 6.7 %北京: 6.7 %南宁: 0.3 %南宁: 0.3 %台州: 1.0 %台州: 1.0 %吉林: 0.7 %吉林: 0.7 %广州: 0.7 %广州: 0.7 %张家口: 2.7 %张家口: 2.7 %德罕: 0.3 %德罕: 0.3 %杭州: 0.7 %杭州: 0.7 %武汉: 0.3 %武汉: 0.3 %湖州: 1.0 %湖州: 1.0 %石家庄: 1.0 %石家庄: 1.0 %绍兴: 0.3 %绍兴: 0.3 %芒廷维尤: 33.4 %芒廷维尤: 33.4 %芝加哥: 0.7 %芝加哥: 0.7 %莫斯科: 1.0 %莫斯科: 1.0 %衢州: 0.3 %衢州: 0.3 %西宁: 38.8 %西宁: 38.8 %诺沃克: 0.3 %诺沃克: 0.3 %长春: 1.0 %长春: 1.0 %长沙: 0.3 %长沙: 0.3 %鞍山: 0.3 %鞍山: 0.3 %其他其他上海丽水北京南宁台州吉林广州张家口德罕杭州武汉湖州石家庄绍兴芒廷维尤芝加哥莫斯科衢州西宁诺沃克长春长沙鞍山

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (274) PDF downloads(287) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2784]YesterdayPV[4482]TodayIP[3186]TodayPV[5837]Online[182]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return